- Home
- ZK vs NUVL Comparison
ZK vs NUVL Comparison
Compare ZK & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZK
- NUVL
- Stock Information
- Founded
- ZK 2017
- NUVL 2017
- Country
- ZK China
- NUVL United States
- Employees
- ZK N/A
- NUVL N/A
- Industry
- ZK
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- ZK
- NUVL Health Care
- Exchange
- ZK NYSE
- NUVL Nasdaq
- Market Cap
- ZK 5.0B
- NUVL 5.5B
- IPO Year
- ZK 2024
- NUVL 2021
- Fundamental
- Price
- ZK $27.42
- NUVL $81.69
- Analyst Decision
- ZK Strong Buy
- NUVL Strong Buy
- Analyst Count
- ZK 2
- NUVL 10
- Target Price
- ZK $32.00
- NUVL $119.60
- AVG Volume (30 Days)
- ZK 412.8K
- NUVL 556.6K
- Earning Date
- ZK 08-20-2025
- NUVL 08-07-2025
- Dividend Yield
- ZK N/A
- NUVL N/A
- EPS Growth
- ZK N/A
- NUVL N/A
- EPS
- ZK N/A
- NUVL N/A
- Revenue
- ZK $10,494,129,543.00
- NUVL N/A
- Revenue This Year
- ZK N/A
- NUVL N/A
- Revenue Next Year
- ZK $28.16
- NUVL N/A
- P/E Ratio
- ZK N/A
- NUVL N/A
- Revenue Growth
- ZK 17.46
- NUVL N/A
- 52 Week Low
- ZK $13.00
- NUVL $55.54
- 52 Week High
- ZK $33.32
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- ZK N/A
- NUVL 60.10
- Support Level
- ZK N/A
- NUVL $78.94
- Resistance Level
- ZK N/A
- NUVL $82.45
- Average True Range (ATR)
- ZK 0.00
- NUVL 2.76
- MACD
- ZK 0.00
- NUVL 0.27
- Stochastic Oscillator
- ZK 0.00
- NUVL 90.66
About ZK ZEEKR INTELLIGENT TECHNOLOGY HLDG L SPON ADS EA REP 10 ORD SHS
ZEEKR Intelligent Technology Holding Ltd is a fast-growing BEV technology company. By developing and offering next-generation premium BEVs and technology-driven solutions, It aspires to lead the automobile industry's electrification, intelligentization and innovation. Since its inception, It has focused on innovation in BEV architecture, hardware, software, and application of new technologies. It is principally engaged in the commercialization and sales of electric vehicles and batteries, and the provision of automotive-related research and development services.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.